Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 216

1.

Vitamin B12 Status in Pregnant Adolescents and Their Infants.

Finkelstein JL, Guillet R, Pressman EK, Fothergill A, Guetterman HM, Kent TR, O'Brien KO.

Nutrients. 2019 Feb 13;11(2). pii: E397. doi: 10.3390/nu11020397.

2.

Iron biofortification interventions to improve iron status and functional outcomes.

Finkelstein JL, Fothergill A, Hackl LS, Haas JD, Mehta S.

Proc Nutr Soc. 2019 May;78(2):197-207. doi: 10.1017/S0029665118002847. Epub 2019 Jan 30.

PMID:
30698117
3.

Erratum for Mor et al., "Identification of a New Class of Antifungals Targeting the Synthesis of Fungal Sphingolipids".

Mor V, Rella A, Farnoud AM, Singh A, Munshi M, Bryan A, Naseem S, Konopka JB, Ojima I, Bullesbach E, Ashbaugh A, Linke MJ, Cushion M, Collins M, Ananthula HK, Sallans L, Desai PB, Wiederhold NP, Fothergill AW, Kirkpatrick WR, Patterson T, Wong LH, Sinha S, Giaever G, Nislow C, Flaherty P, Pan X, Cesar GV, de Melo Tavares P, Frases S, Miranda K, Rodrigues ML, Luberto C, Nimrichter L, Del Poeta M.

MBio. 2018 Mar 13;9(2). pii: e00188-18. doi: 10.1128/mBio.00188-18. No abstract available.

4.

Impact of cancer treatment on risk of infertility and diminished ovarian reserve in women with polycystic ovary syndrome.

Shandley LM, Fothergill A, Spencer JB, Mertens AC, Cottrell HN, Howards PP.

Fertil Steril. 2018 Mar;109(3):516-525.e1. doi: 10.1016/j.fertnstert.2017.11.016. Epub 2018 Feb 7.

5.

Conducting Science in Disasters: Recommendations from the NIEHS Working Group for Special IRB Considerations in the Review of Disaster Related Research.

Packenham JP, Rosselli RT, Ramsey SK, Taylor HA, Fothergill A, Slutsman J, Miller A.

Environ Health Perspect. 2017 Sep 25;125(9):094503. doi: 10.1289/EHP2378.

6.

Outbreaks attributed to pork in the United States, 1998-2015.

Self JL, Luna-Gierke RE, Fothergill A, Holt KG, Vieira AR.

Epidemiol Infect. 2017 Oct;145(14):2980-2990. doi: 10.1017/S0950268817002114. Epub 2017 Sep 14.

PMID:
28903784
7.

The risk of preterm birth and growth restriction in pregnancy after cancer.

Hartnett KP, Ward KC, Kramer MR, Lash TL, Mertens AC, Spencer JB, Fothergill A, Howards PP.

Int J Cancer. 2017 Dec 1;141(11):2187-2196. doi: 10.1002/ijc.30914. Epub 2017 Aug 24.

8.

"Research on Infertility: Definition Makes a Difference" Revisited.

Jacobson MH, Chin HB, Mertens AC, Spencer JB, Fothergill A, Howards PP.

Am J Epidemiol. 2018 Feb 1;187(2):337-346. doi: 10.1093/aje/kwx240.

9.

Impact of tamoxifen therapy on fertility in breast cancer survivors.

Shandley LM, Spencer JB, Fothergill A, Mertens AC, Manatunga A, Paplomata E, Howards PP.

Fertil Steril. 2017 Jan;107(1):243-252.e5. doi: 10.1016/j.fertnstert.2016.10.020. Epub 2016 Nov 22.

10.

Anterior eye tissue morphology: Scleral and conjunctival thickness in children and young adults.

Read SA, Alonso-Caneiro D, Vincent SJ, Bremner A, Fothergill A, Ismail B, McGraw R, Quirk CJ, Wrigley E.

Sci Rep. 2016 Sep 20;6:33796. doi: 10.1038/srep33796.

11.

The Celecoxib Derivative AR-12 Has Broad-Spectrum Antifungal Activity In Vitro and Improves the Activity of Fluconazole in a Murine Model of Cryptococcosis.

Koselny K, Green J, DiDone L, Halterman JP, Fothergill AW, Wiederhold NP, Patterson TF, Cushion MT, Rappelye C, Wellington M, Krysan DJ.

Antimicrob Agents Chemother. 2016 Nov 21;60(12):7115-7127. Print 2016 Dec.

12.

Repurposing auranofin as an antifungal: In vitro activity against a variety of medically important fungi.

Wiederhold NP, Patterson TF, Srinivasan A, Chaturvedi AK, Fothergill AW, Wormley FL, Ramasubramanian AK, Lopez-Ribot JL.

Virulence. 2017 Feb 17;8(2):138-142. doi: 10.1080/21505594.2016.1196301. Epub 2016 Jun 7.

13.

Voriconazole minimum inhibitory concentrations are predictive of treatment outcome in experimental murine infections by Candida glabrata.

Sanchis M, Capilla J, Castanheira M, Martin-Vicente A, Sutton DA, Fothergill AW, Wiederhold NP, Guarro J.

Int J Antimicrob Agents. 2016 Apr;47(4):286-8. doi: 10.1016/j.ijantimicag.2015.12.020. Epub 2016 Feb 21.

PMID:
26976780
14.

The Investigational Fungal Cyp51 Inhibitor VT-1129 Demonstrates Potent In Vitro Activity against Cryptococcus neoformans and Cryptococcus gattii.

Lockhart SR, Fothergill AW, Iqbal N, Bolden CB, Grossman NT, Garvey EP, Brand SR, Hoekstra WJ, Schotzinger RJ, Ottinger E, Patterson TF, Wiederhold NP.

Antimicrob Agents Chemother. 2016 Mar 25;60(4):2528-31. doi: 10.1128/AAC.02770-15. Print 2016 Apr.

15.

Effects of Treated versus Untreated Polystyrene on Caspofungin In Vitro Activity against Candida Species.

Fothergill AW, McCarthy DI, Albataineh MT, Sanders C, McElmeel M, Wiederhold NP.

J Clin Microbiol. 2016 Mar;54(3):734-8. doi: 10.1128/JCM.02659-15. Epub 2016 Jan 13.

16.

Update from the Laboratory: Clinical Identification and Susceptibility Testing of Fungi and Trends in Antifungal Resistance.

Albataineh MT, Sutton DA, Fothergill AW, Wiederhold NP.

Infect Dis Clin North Am. 2016 Mar;30(1):13-35. doi: 10.1016/j.idc.2015.10.014. Epub 2015 Dec 29. Review.

PMID:
26739605
17.

Multilaboratory Evaluation of In Vitro Antifungal Susceptibility Testing of Dermatophytes for ME1111.

Ghannoum M, Chaturvedi V, Diekema D, Ostrosky-Zeichner L, Rennie R, Walsh T, Wengenack N, Fothergill A, Wiederhold N.

J Clin Microbiol. 2016 Mar;54(3):662-5. doi: 10.1128/JCM.03019-15. Epub 2015 Dec 30.

18.

The novel arylamidine T-2307 demonstrates in vitro and in vivo activity against echinocandin-resistant Candida glabrata.

Wiederhold NP, Najvar LK, Fothergill AW, Bocanegra R, Olivo M, McCarthy DI, Fukuda Y, Mitsuyama J, Patterson TF.

J Antimicrob Chemother. 2016 Mar;71(3):692-5. doi: 10.1093/jac/dkv398. Epub 2015 Nov 29.

19.

First Detection of TR34 L98H and TR46 Y121F T289A Cyp51 Mutations in Aspergillus fumigatus Isolates in the United States.

Wiederhold NP, Gil VG, Gutierrez F, Lindner JR, Albataineh MT, McCarthy DI, Sanders C, Fan H, Fothergill AW, Sutton DA.

J Clin Microbiol. 2016 Jan;54(1):168-71. doi: 10.1128/JCM.02478-15. Epub 2015 Oct 21.

20.

Voriconazole and posaconazole therapy for experimental Candida lusitaniae infection.

Sanchis M, Guarro J, Sutton DA, Fothergill AW, Wiederhold N, Capilla J.

Diagn Microbiol Infect Dis. 2016 Jan;84(1):48-51. doi: 10.1016/j.diagmicrobio.2015.09.010. Epub 2015 Sep 18.

PMID:
26456387
21.

VT-1161 Protects Immunosuppressed Mice from Rhizopus arrhizus var. arrhizus Infection.

Gebremariam T, Wiederhold NP, Fothergill AW, Garvey EP, Hoekstra WJ, Schotzinger RJ, Patterson TF, Filler SG, Ibrahim AS.

Antimicrob Agents Chemother. 2015 Dec;59(12):7815-7. doi: 10.1128/AAC.01437-15. Epub 2015 Sep 14.

22.

Evaluation of VT-1161 for Treatment of Coccidioidomycosis in Murine Infection Models.

Shubitz LF, Trinh HT, Galgiani JN, Lewis ML, Fothergill AW, Wiederhold NP, Barker BM, Lewis ER, Doyle AL, Hoekstra WJ, Schotzinger RJ, Garvey EP.

Antimicrob Agents Chemother. 2015 Dec;59(12):7249-54. doi: 10.1128/AAC.00593-15. Epub 2015 Sep 14.

23.

Detection of triazole resistance among Candida species by matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF MS).

Saracli MA, Fothergill AW, Sutton DA, Wiederhold NP.

Med Mycol. 2015 Sep;53(7):736-42. doi: 10.1093/mmy/myv046. Epub 2015 Jul 10.

PMID:
26162474
24.

Identification of a New Class of Antifungals Targeting the Synthesis of Fungal Sphingolipids.

Mor V, Rella A, Farnoud AM, Singh A, Munshi M, Bryan A, Naseem S, Konopka JB, Ojima I, Bullesbach E, Ashbaugh A, Linke MJ, Cushion M, Collins M, Ananthula HK, Sallans L, Desai PB, Wiederhold NP, Fothergill AW, Kirkpatrick WR, Patterson T, Wong LH, Sinha S, Giaever G, Nislow C, Flaherty P, Pan X, Cesar GV, de Melo Tavares P, Frases S, Miranda K, Rodrigues ML, Luberto C, Nimrichter L, Del Poeta M.

MBio. 2015 Jun 23;6(3):e00647. doi: 10.1128/mBio.00647-15. Erratum in: MBio. 2018 Mar 13;9(2):.

25.

A guide to critiquing a research paper. Methodological appraisal of a paper on nurses in abortion care.

Lipp A, Fothergill A.

Nurse Educ Today. 2015 Mar;35(3):e14-7. doi: 10.1016/j.nedt.2014.12.010. Epub 2015 Jan 24. Review.

PMID:
25638278
26.

Multicenter evaluation of MIC distributions for epidemiologic cutoff value definition to detect amphotericin B, posaconazole, and itraconazole resistance among the most clinically relevant species of Mucorales.

Espinel-Ingroff A, Chakrabarti A, Chowdhary A, Cordoba S, Dannaoui E, Dufresne P, Fothergill A, Ghannoum M, Gonzalez GM, Guarro J, Kidd S, Lass-Flörl C, Meis JF, Pelaez T, Tortorano AM, Turnidge J.

Antimicrob Agents Chemother. 2015 Mar;59(3):1745-50. doi: 10.1128/AAC.04435-14. Epub 2015 Jan 12.

27.

The novel arylamidine T-2307 maintains in vitro and in vivo activity against echinocandin-resistant Candida albicans.

Wiederhold NP, Najvar LK, Fothergill AW, Bocanegra R, Olivo M, McCarthy DI, Kirkpatrick WR, Fukuda Y, Mitsuyama J, Patterson TF.

Antimicrob Agents Chemother. 2015 Feb;59(2):1341-3. doi: 10.1128/AAC.04228-14. Epub 2014 Dec 1.

28.

The investigational agent E1210 is effective in treatment of experimental invasive candidiasis caused by resistant Candida albicans.

Wiederhold NP, Najvar LK, Fothergill AW, McCarthy DI, Bocanegra R, Olivo M, Kirkpatrick WR, Everson MP, Duncanson FP, Patterson TF.

Antimicrob Agents Chemother. 2015 Jan;59(1):690-2. doi: 10.1128/AAC.03944-14. Epub 2014 Oct 20.

29.

Epidemiology and outcome of systemic infections due to saprochaete capitata: case report and review of the literature.

Mazzocato S, Marchionni E, Fothergill AW, Sutton DA, Staffolani S, Gesuita R, Skrami E, Fiorentini A, Manso E, Barchiesi F.

Infection. 2015 Apr;43(2):211-5. doi: 10.1007/s15010-014-0668-3. Epub 2014 Jul 31. Review.

PMID:
25078793
30.

Experimental therapy with azoles against Candida guilliermondii.

Sanchis M, Pastor FJ, Capilla J, Sutton DA, Fothergill AW, Guarro J.

Antimicrob Agents Chemother. 2014 Oct;58(10):6255-7. doi: 10.1128/AAC.03051-14. Epub 2014 Jul 21.

31.

Experimental treatment of Curvularia infection.

Paredes K, Capilla J, Sutton DA, Mayayo E, Fothergill AW, Guarro J.

Diagn Microbiol Infect Dis. 2014 Aug;79(4):428-31. doi: 10.1016/j.diagmicrobio.2014.05.004. Epub 2014 May 17.

PMID:
24938759
32.

A guide to critiquing a research paper on clinical supervision: enhancing skills for practice.

Fothergill A, Lipp A.

J Psychiatr Ment Health Nurs. 2014;21(9):834-40. doi: 10.1111/jpm.12161. Epub 2014 May 13.

PMID:
24818837
33.

In vitro antifungal susceptibility of Candida glabrata to caspofungin and the presence of FKS mutations correlate with treatment response in an immunocompromised murine model of invasive infection.

Fernández-Silva F, Lackner M, Capilla J, Mayayo E, Sutton D, Castanheira M, Fothergill AW, Lass-Flörl C, Guarro J.

Antimicrob Agents Chemother. 2014 Jul;58(7):3646-9. doi: 10.1128/AAC.02666-13. Epub 2014 Apr 14.

34.

Phylogeny of the clinically relevant species of the emerging fungus Trichoderma and their antifungal susceptibilities.

Sandoval-Denis M, Sutton DA, Cano-Lira JF, Gené J, Fothergill AW, Wiederhold NP, Guarro J.

J Clin Microbiol. 2014 Jun;52(6):2112-25. doi: 10.1128/JCM.00429-14. Epub 2014 Apr 9.

35.

Luliconazole demonstrates potent in vitro activity against dermatophytes recovered from patients with onychomycosis.

Wiederhold NP, Fothergill AW, McCarthy DI, Tavakkol A.

Antimicrob Agents Chemother. 2014 Jun;58(6):3553-5. doi: 10.1128/AAC.02706-13. Epub 2014 Apr 7.

36.

Therapies against murine Candida guilliermondii infection, relationship between in vitro antifungal pharmacodynamics and outcome.

Paredes K, Pastor FJ, Capilla J, Sutton DA, Mayayo E, Fothergill AW, Guarro J.

Rev Iberoam Micol. 2015 Jan-Mar;32(1):34-9. doi: 10.1016/j.riam.2013.10.008. Epub 2014 Mar 1.

PMID:
24594291
37.

Reply to Ma et al.: osteomyelitis caused by Aspergillus species.

Gabrielli E, Fothergill AW, Brescini L, Sutton DA, Marchionni E, Orsetti E, Staffolani S, Castelli P, Gesuita R, Barchiesi F.

Clin Microbiol Infect. 2014 Oct;20(10):O788. doi: 10.1111/1469-0691.12613. Epub 2014 Mar 26. No abstract available.

38.

Multilaboratory study of epidemiological cutoff values for detection of resistance in eight Candida species to fluconazole, posaconazole, and voriconazole.

Espinel-Ingroff A, Pfaller MA, Bustamante B, Canton E, Fothergill A, Fuller J, Gonzalez GM, Lass-Flörl C, Lockhart SR, Martin-Mazuelos E, Meis JF, Melhem MS, Ostrosky-Zeichner L, Pelaez T, Szeszs MW, St-Germain G, Bonfietti LX, Guarro J, Turnidge J.

Antimicrob Agents Chemother. 2014;58(4):2006-12. doi: 10.1128/AAC.02615-13. Epub 2014 Jan 13.

39.

Impact of new antifungal breakpoints on antifungal resistance in Candida species.

Fothergill AW, Sutton DA, McCarthy DI, Wiederhold NP.

J Clin Microbiol. 2014 Mar;52(3):994-7. doi: 10.1128/JCM.03044-13. Epub 2014 Jan 8.

40.

In vitro pharmacodynamics and in vivo efficacy of fluconazole, amphotericin B and caspofungin in a murine infection by Candida lusitaniae.

Sandoval-Denis M, Pastor FJ, Capilla J, Sutton DA, Fothergill AW, Guarro J.

Int J Antimicrob Agents. 2014 Feb;43(2):161-4. doi: 10.1016/j.ijantimicag.2013.10.024. Epub 2013 Nov 26.

PMID:
24360922
41.

Osteomyelitis caused by Aspergillus species: a review of 310 reported cases.

Gabrielli E, Fothergill AW, Brescini L, Sutton DA, Marchionni E, Orsetti E, Staffolani S, Castelli P, Gesuita R, Barchiesi F.

Clin Microbiol Infect. 2014 Jun;20(6):559-65. doi: 10.1111/1469-0691.12389. Epub 2013 Oct 15. Review.

42.

Multicenter study of anidulafungin and micafungin MIC distributions and epidemiological cutoff values for eight Candida species and the CLSI M27-A3 broth microdilution method.

Pfaller MA, Espinel-Ingroff A, Bustamante B, Canton E, Diekema DJ, Fothergill A, Fuller J, Gonzalez GM, Guarro J, Lass-Flörl C, Lockhart SR, Martin-Mazuelos E, Meis JF, Ostrosky-Zeichner L, Pelaez T, St-Germain G, Turnidge J.

Antimicrob Agents Chemother. 2014;58(2):916-22. doi: 10.1128/AAC.02020-13. Epub 2013 Nov 25.

43.

A reference laboratory experience of clinically achievable voriconazole, posaconazole, and itraconazole concentrations within the bloodstream and cerebral spinal fluid.

Wiederhold NP, Pennick GJ, Dorsey SA, Furmaga W, Lewis JS 2nd, Patterson TF, Sutton DA, Fothergill AW.

Antimicrob Agents Chemother. 2014;58(1):424-31. doi: 10.1128/AAC.01558-13. Epub 2013 Nov 4.

44.

In vitro antifungal susceptibility of clinical isolates of Arthrographis kalrae, a poorly known opportunistic fungus.

Sandoval-Denis M, Giraldo A, Sutton DA, Fothergill AW, Guarro J.

Mycoses. 2014 Apr;57(4):247-8. doi: 10.1111/myc.12151. Epub 2013 Oct 22.

PMID:
24147779
45.

Scopulariopsis, a poorly known opportunistic fungus: spectrum of species in clinical samples and in vitro responses to antifungal drugs.

Sandoval-Denis M, Sutton DA, Fothergill AW, Cano-Lira J, Gené J, Decock CA, de Hoog GS, Guarro J.

J Clin Microbiol. 2013 Dec;51(12):3937-43. doi: 10.1128/JCM.01927-13. Epub 2013 Sep 11.

46.

Interlaboratory variability of Caspofungin MICs for Candida spp. Using CLSI and EUCAST methods: should the clinical laboratory be testing this agent?

Espinel-Ingroff A, Arendrup MC, Pfaller MA, Bonfietti LX, Bustamante B, Canton E, Chryssanthou E, Cuenca-Estrella M, Dannaoui E, Fothergill A, Fuller J, Gaustad P, Gonzalez GM, Guarro J, Lass-Flörl C, Lockhart SR, Meis JF, Moore CB, Ostrosky-Zeichner L, Pelaez T, Pukinskas SR, St-Germain G, Szeszs MW, Turnidge J.

Antimicrob Agents Chemother. 2013 Dec;57(12):5836-42. doi: 10.1128/AAC.01519-13. Epub 2013 Sep 9.

47.

Rapid identification of antifungal compounds against Exserohilum rostratum using high throughput drug repurposing screens.

Sun W, Park YD, Sugui JA, Fothergill A, Southall N, Shinn P, McKew JC, Kwon-Chung KJ, Zheng W, Williamson PR.

PLoS One. 2013 Aug 21;8(8):e70506. doi: 10.1371/journal.pone.0070506. eCollection 2013. Erratum in: PLoS One. 2013;8(9). doi:10.1371/annotation/df5a5a46-cf30-4842-bf11-b6cee36c1f9b.

48.

Evaluation of the correlation of caspofungin MICs and treatment outcome in murine infections by wild type strains of Candida parapsilosis.

Salas V, Pastor FJ, Capilla J, Sutton DA, Mayayo E, Fothergill AW, Rinaldi MG, Guarro J.

Diagn Microbiol Infect Dis. 2013 Sep;77(1):41-5. doi: 10.1016/j.diagmicrobio.2013.05.011. Epub 2013 Jun 24.

PMID:
23806662
49.

Comparison of MICs of fluconazole and flucytosine when dissolved in dimethyl sulfoxide or water.

Fothergill AW, Sanders C, Wiederhold NP.

J Clin Microbiol. 2013 Jun;51(6):1955-7. doi: 10.1128/JCM.00260-13. Epub 2013 Apr 10.

50.

In vitro antifungal susceptibility and molecular identity of 99 clinical isolates of the opportunistic fungal genus Curvularia.

da Cunha KC, Sutton DA, Fothergill AW, Gené J, Cano J, Madrid H, Hoog Sd, Crous PW, Guarro J.

Diagn Microbiol Infect Dis. 2013 Jun;76(2):168-74. doi: 10.1016/j.diagmicrobio.2013.02.034. Epub 2013 Apr 1.

PMID:
23558007

Supplemental Content

Loading ...
Support Center